Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

40.18 +0.17 (+0.42%)
Official Closing Price Updated: 7:00 PM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Ziprasidone Market Trends Share Demand Overview Analysis 2022-2029
Global Ziprasidone Market to Witness Huge Growth by Key Players: Pfizer Inc., Sandoz AG, Lupin Pharmaceuticals, Inc., Mylan Pharmaceuticals, Apotex, Dr. Reddy's laboratories Ltd., Wockhardt, Aurobindo... 
Via SBWire
Spinal Stenosis Treatment Market to Grow with a Growth Rate of 4% During 2022 to 2029
Spinal Stenosis Treatment Market size was valued USD million in 2021 and is estimated to reach USD million by 2029, growing at a CAGR of 4% during the forecast period (2022-2029). 
Via SBWire
Undifferentiated Pleomorphic Sarcoma Therapeutics Market Share Volume Demand 2022 to 2029
The Undifferentiated Pleomorphic Sarcoma Therapeutics Market size was valued USD million in 2021 and is estimated to reach USD million by 2029, growing at a high CAGR during the forecast period... 
Via SBWire
Acurx is Setting a High Bar for New Treatments in C. diff
A New Gold Standard for C. diff Therapy Could be in the Offing;  Next Data Release Expected in 2Q23 
Via Benzinga
Is This the Telltale Sign to Sell Novavax Stock?
You won't find Novavax's latest bad news trumpeted in a press release. 
Via The Motley Fool
Is This Dividend Stock a No-Brainer Buy?
This company led the battle against COVID-19. 
Via The Motley Fool
Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers
Large cap biopharma stocks are off their highs despite reasonable valuations plus dividends. 
Via Talk Markets
Water for Injection Market Trends Outlook Demand 2023 -2030
Global Water for Injection Market to Witness Huge Growth by Key Players: Abbott Laboratories, AdvaCare Pharma, B. Braun SE, FUJIFILM Holdings Corp., GlaxoSmithKline Plc, Merit Healthcare International... 
Via SBWire
These Cheap Growth Stocks Could Supercharge Your Portfolio
All of these players are cheap today considering their growth potential. 
Via The Motley Fool
Is The Bear Market Rally Over?
Financials have yet to break. 
Via Talk Markets
FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib)
From Pfizer Inc.
Via Business Wire
Gemcitabine HCL Market to Grow with a Growth Rate of 7% During 2023 to 2030
Gemcitabine HCL Market size is expected to reach at a CAGR of 7% during the forecast period (2023-2030). 
Via SBWire
Multi-platinum Singer and Songwriter Ally Brooke Hernandez Shares her Migraine Journey to Help the Latino Community Living with Disease
(BPT) - Content sponsored and provided by Pfizer. Ally Brooke Hernandez has partnered with Pfizer to share her experience living with migraine. 
Via Brandpoint
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
By Julian Richard, Benzinga 
Via TheNewswire.com
Topics Intellectual Property
Exposures Intellectual Property
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
BioRestorative Therapies (NASDAQ: BRTX), a clinical-stage biotechnology company focused on stem cell-based therapies, announced on the 8th of February that the European Patent Office had issued a... 
Via Benzinga
Is Novavax Stock a Buy With the New Normal for COVID?
The landscape has shifted dramatically in the COVID-19 vaccine market. 
Via The Motley Fool
Europe Liver Cancer Therapeutics Market to Reach at High CAGR of 8.95% by 2023-2030
The Europe liver cancer therapeutics size was valued at US$ 384 million in 2022 and is estimated to reach US$ 627 million by 2030, growing at a CAGR of 8.95% during the forecast period (2023-2030) 
Via SBWire
2 Excellent Stocks to Buy in 2023 and Never Sell
If your favorite investment period is "forever," check out these two stocks. 
Via The Motley Fool
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
3 Healthcare Stocks That Are Too Cheap to Ignore
Pay attention when stocks have these kinds of low valuations. 
Via The Motley Fool
Thoughts For Thursday: Risk-off, Risk-on
The one foot forward, one foot backward action continues on Wall Street, though yesterday it was more like three or four steps backward. It seems Q1 earnings jitters are responsible. 
Via Talk Markets
A Look At Pharma ETFs Post Q4 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month. 
Via Talk Markets
NeurAxis: Should You Buy This IPO?
As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype. 
Via Talk Markets
Musculoskeletal Diseases Treatment Market Is Poised to Cross at High CAGR of 4.9% in 2023-2030
The Musculoskeletal Diseases Treatment Market size was valued at US$ YY million in 2023 and is estimated to reach US$ YY million by 2030, growing at a CAGR of 4.8% during the forecast period... 
Via SBWire
Pain Relief Medication Market to Witness Huge Growth by Key Players: Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline Plc.
Global Pain Relief Medication Market By Material (Acute, Chronic), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) 
Via SBWire
Active Pharmaceutical Ingredients Market May Set Epic Growth Story : Pfizer, Novartis, Sanofi
Stay up-to-date with Active Pharmaceutical Ingredients Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Topics Death
Exposures Death
Benzinga's Top Ratings Upgrades, Downgrades For February 7, 2023
 
Via Benzinga
This Healthcare Giant Expects Revenue to Crash More Than 30% This Year
Could Pfizer be a cheap contrarian stock to buy? 
Via The Motley Fool
3 Bargain Stocks to Snap Up Before the Crowd Gets Wise
One of the best ways to make money in 2023 is by picking up ridiculous bargain stocks in some of the hottest industries. Here are three. 
Via InvestorPlace
NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution
As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.